Market Research Report
US Acne & Rosacea Market: Insights, Trends & Forecast (2020-2024)
|Published by||Koncept Analytics||Product code||952549|
|Published||Content info||133 Pages
Delivery time: 1-2 business days
|US Acne & Rosacea Market: Insights, Trends & Forecast (2020-2024)|
|Published: August 3, 2020||Content info: 133 Pages||
The US acne market is expected to reach US$4.49 billion in 2024, recording growth at a CAGR of 4.12% during the period spanning 2019-2024. The US rosacea market is expected to reach US$1.80 billion in 2024, growing at a CAGR of 5.92% during the period spanning 2019-2024. Growth in the acne and rosacea market has accrued due to the rising youth population, increasing purchasing power of the consumers and escalating healthcare expenditure. The market is anticipated to experience certain trends like growing awareness about acne & rosacea and their treatments and increasing importance of personal appearance. The US acne & rosacea market would face challenges regarding entry of generic drugs and side effects of therapies.
The US acne market by drug type can be segmented as follows: topical drugs and oral antibiotics. In 2019, the higher share of the market was held by topical drugs, followed by oral antibiotics. The US acne topical drugs by brand can be segmented into the following: Epiduo Franchise, Aczone Franchise, Retin-A-Franchise, Onextin/Acanya and Veltin. In 2019, the dominant share was held by Epiduo Franchise, followed by Aczone Franchise. The US acne oral antibiotics by brand can be segmented as follows: Solodyn, Acticlate, Doryx Franchise and Targadox. The highest share of the market was held by Solodyn, followed by Acticlate and Doryx Franchise. The US acne addressable population by severity can be segmented as follows: moderate patients, mild patients and severe patients. The largest share of market was held by moderate patients.
The US rosacea market by drug type can be segmented as follows: topical drugs and oral antibiotics. The dominant share of the market was held by topical drugs segment in 2019. The US rosacea drug revenue by brand can be segmented into following: Metrogel, Oracea, Soolantra, Finacea, Vasoconstrictors and Minocycline. In 2019, the dominant share of the revenue was generated by Metrogel, followed by Oracea.